May 22, 2023London Stock Exchange Delisting May 19, 2023Commencement of trading of new ordinary shares on The Nasdaq Capital Market May 15, 2023Change of Record Time and Last Day of Dealings May 11, 2023OKYO Pharma Now Participating on the Webull Corporate Communications Service Platform May 11, 2023Change of Delisting Date to 22 May 2023 May 3, 2023Result of General Meeting May 3, 2023OKYO Pharma Announces Presentations at the American Society of Cataract and Refractive Surgery (ASCRS 2023) in San Diego, CA, May 5-8, 2023 May 2, 2023OKYO Pharma Announces First-Patient First-Visit for Phase 2 Trial Evaluating Efficacy and Safety of OK-101 in Patients with Dry Eye Disease April 25, 2023OKYO Pharma Announces Activation of First Clinical Trial Site in the U.S. for the Phase 2 Trial Evaluating OK-101 for the Treatment of Dry Eye Disease April 5, 2023NOTICE OF GENERAL MEETING AND PUBLICATION OF CIRCULAR April 4, 2023NOTICE OF INTENTION TO DELIST FROM THE LONDON STOCK EXCHANGE March 30, 2023OKYO Pharma Today Announces Director Acquires Shares March 29, 2023OKYO Pharma Today Announces Director Acquires Shares March 24, 2023OKYO Pharma Announces PDMR Dealing March 16, 2023OKYO Pharma Announces Phase 2 Trial of OK-101 Drug to Treat Dry Eye Disease is now listed on the ClinicalTrials.gov Public Website. March 16, 2023Closing of Global Private Placement March 15, 2023OKYO Pharma announces that the board of directors of the Company, acting on a recommendation of the Remuneration Committee has awarded options to directors and persons discharging managerial responsibility. March 14, 2023OKYO Pharma Limited announces U.S.$5.74 million Global Private Placement and investment by directors and members of senior management March 13, 2023CEO of OKYO Pharma, Inc., Dr. Gary Jacob, Interviewed by Leading Publisher,SmallCapsDaily February 28, 2023OKYO Pharma Announces Custom Clearance of GMP Packaged OK-101 Drug to be Used in Phase 2 Clinical Trial for Treating Dry Eye Disease February 23, 2023World-renowned Ophthalmologist with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Joins Advisory Board of OKYO Pharma February 21, 2023OKYO Pharma to Present at the Second Annual GPCRs-Targeted Drug Discovery Summit in Boston, MA on February 21-23, 2023. February 14, 2023Allotment of Shares and Total Voting Rights December 30, 2022Interim Results for the Six Months Ending 30 September 2022 December 22, 2022OKYO Pharma Announces U.S. FDA Clearance of IND Application for OK-101 for the Treatment of Dry Eye Disease December 21, 2022OKYO to Participate at Biotech Showcase December 6, 2022OKYO publicly files a registration statement with the SEC December 1, 2022Change of Auditor November 24, 2022Grant of options –PDMR dealing November 21, 2022OKYO Pharma Announces U.S. IND Filing on OK-101 for the Treatment of Dry Eye Disease November 10, 2022OKYO Pharma Hosting Key Opinion Leader Event Introducing OK-101 as a Potential Treatment for Dry Eye Disease October 20, 2022OKYO Pharma Ltd. Announces Participation in The ThinkEquity Conference September 8, 2022OKYO Pharma Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report® September 7, 2022Result of Annual General Meeting August 30, 2022OKYO Pharma Plans Q4 2022 IND Filing of OK-101 to treat Dry Eye Disease with Subsequent Phase 2 Initiation Alongside Peptide Manufacturing Partner, AmbioPharm August 19, 2022Notice of Annual General Meeting August 16, 2022Final audited results for the year ended 31 March 2022 June 9, 2022PDMR Dealing May 20, 2022PDMR Dealing May 19, 2022OKYO Pharma Limited Announces Closing of Public Offering and Nasdaq Listing May 18, 2022PDMR Dealing May 17, 2022OKYO Pharma Limited Announces Pricing of Initial Public Offering of ADSs in the U.S. with director participation April 27, 2022OKYO Pharma Announces Two Presentations at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting March 7, 2022OKYO publicly files a registration statement with the SEC for a proposed dual-listing on the Nasdaq Capital Market and Offering in the United States February 23, 2022OKYO Pharma announces issuance of U.S. Patent No. 11,254,720 covering OKYO’s dry eye drug candidate OK-101 for use to treat ocular neuropathic pain February 21, 2022Conversion of CLNs, cashless exercise of Warrants, and issue of equity February 15, 2022Successful Completion of a Pre-IND Meeting with the FDA on the Development of OK-101 to Treat Dry Eye Disease February 1, 2022Grant of options – Director and PDMR dealings January 27, 2022PDMR Dealing January 26, 2022OKYO Pharma Limited: Interim results for the six months to 30 September 2021 December 14, 2021Issuance of U.S. Patent No. 11,197,906 covering OKYO Pharma’s drug candidate OK-101 for use to treat dry eye disease December 13, 2021First-in-Class Drug Candidate OK-101 Displaying Both Anti-inflammatory and Ocular Pain-Reducing Potential to Treat Dry Eye Disease December 6, 2021OKYO to File IND in Q3 2022 for OK-101 to treat Dry Eye Disease (“DED”) and to go directly to a Phase 2 Human Clinical Efficacy Trial in DED Patients with a planned start date in Q4 2022 on an accelerated basis December 1, 2021DIRECTORATE CHANGE September 27, 2021Result of Annual General Meeting September 9, 2021Notice of Annual General Meeting September 1, 2021Grant of options – Director dealings August 2, 2021Final audited results for the year ended 31 March 2021 June 29, 2021OKYO Pharma Retains Ora Inc. to Perform Regulatory Development of OK-101 for Dry Eye Indications June 17, 2021DIRECTORATE CHANGE May 12, 2021TR-1: Standard form for notification of major holdings May 7, 2021Admission of additional shares to listing on the Official List and to trading on the London Stock Exchange and director dealing May 5, 2021Prospectus Publication Announcement April 28, 2021OKYO Pharma Announces Positive Data and Results in an Animal Model using Topically Administered OK-201 to Treat Neuropathic Ocular Pain March 29, 2021OKYO announces appointment of Dr Rajkumar Patil as Chief Scientific Officer March 10, 2021OKYO Pharma Limited CEO Gary Jacob tells Proactive’s Andrew Scott it’s time to take the company from development stage and into the clinic March 3, 2021ISSUE OF EQUITY – UPDATE March 1, 2021ISSUE OF EQUITY February 23, 2021OKYO Pharma has U.S. Patent Issued Covering its Lipid Conjugated Peptide Analogues for treating Ocular Pain and Inflammation January 19, 2021OKYO announces filing of a patent application covering the use of Chemerin and associated analogues to treat “cytokine storm” associated with COVID-19 and ARDS January 7, 2021DIRECTORATE CHANGES AND PDMR DEALING November 30, 2020Interim results for the six months to 30 September 2020 September 25, 2020Upload of Articles of Association to National Storage Mechanism September 25, 2020RESULT OF THE ANNUAL GENERAL MEETING September 9, 2020Notice of Annual General Meeting September 8, 2020Issue of convertible loan notes to raise an additional £500,000 August 21, 2020Grant of options – Director dealings August 19, 2020Appointment of Dr. Napoleone Ferrara to Serve on Its Scientific Advisory Board August 18, 2020Issue of additional convertible loan notes to raise £1,437,104 and intention to seek dual listing on NASDAQ August 17, 2020Final audited results for the year ended 31 March 2020 August 7, 2020Dr James Khodabakhsh MD named Chairman of the SAB August 6, 2020Holding(s) in Company August 3, 2020Company Presentation July 31, 2020Upcoming Presentation July 28, 2020Issue of convertible loan notes to raise £3,500,000 June 10, 2020DIRECTORATE CHANGE June 5, 2020TR-1: Standard form for notification of major holdings June 3, 2020Appointment of Broker May 29, 2020Issue of convertible loan notes to raise £440,000 May 28, 2020Balance of Placing to raise £560,000 announced on 23 March 2020 May 27, 2020TR-1: Standard form for notification of major holdings April 27, 2020TR-1: Standard form for notification of major holdings March 30, 2020TR-1: Standard form for notification of major holdings March 23, 2020Update on Placing to raise £560,000 March 19, 2020Placing to raise £560,000 March 2, 2020Result of Annual General Meeting December 19, 2019DIRECTORATE CHANGE November 29, 2019Interim results for the six months to 30 September 2019 August 28, 2019OKYO Pharma Announces Potent Anti-inflammatory Effects of OK-113, a Novel Agonist of Chemerin G-Protein Coupled Receptor, in a Mouse Model of Dry Eye Disease August 19, 2019OKYO Pharma Announces Collaboration with Prof. Pedram Hamrah to Evaluate Proprietary Lead Compounds as Non-Opioid Analgesics Targeting G-Protein Coupled Receptors July 1, 2019Final audited results for the year ended 31 March 2019 May 30, 2019TR-1 – Notification of Major Holdings May 20, 2019Result of General Meeting, Admission of Subscription Shares and Total Voting Rights April 26, 2019Subscription of 36,363,636 new Ordinary Shares at a price of 1.1 pence per share to raise gross proceeds of £400,000 Proposed Approval of Waiver of the obligations under Rule 9 of the Takeover Code and Notice of General Meeting March 14, 2019OKYO releases preclinical data on OKYO-0101 at the 14th Congress on Ocular Pharmacology and Therapeutics, 2019 demonstrating its potential to treat dry eye. March 7, 2019Presentation of Preclinical Data Demonstrating Potential of OKYO-0101 for Dry Eye Treatment January 23, 2019OKYO Pharma Corporate Update November 30, 2018Interim results for the six months to 30 September 2018 November 1, 2018Expected Admission Date for Consideration Shares October 24, 2018Allotment of ordinary shares and listing application September 12, 2018OKYO Pharma sees big opportunities for its dry eye and pain management technology September 6, 2018Result of AGM August 22, 2018Notification of Major Holdings
Corporate Presentation Download Presentation Videos OKYO Pharma reaches milestone with first patient screening for dry eye disease trial OKYO Pharma granted new patent for OK-101 to treat neuropathic pain OKYO Pharma to take dry eye disease drug direct into Phase 2 clinical trials